JP2020517289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517289A5
JP2020517289A5 JP2019558446A JP2019558446A JP2020517289A5 JP 2020517289 A5 JP2020517289 A5 JP 2020517289A5 JP 2019558446 A JP2019558446 A JP 2019558446A JP 2019558446 A JP2019558446 A JP 2019558446A JP 2020517289 A5 JP2020517289 A5 JP 2020517289A5
Authority
JP
Japan
Prior art keywords
cells
nucleic acid
cell
codon
guide rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019558446A
Other languages
English (en)
Japanese (ja)
Other versions
JP7457302B2 (ja
JP2020517289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/029302 external-priority patent/WO2018200635A1/en
Publication of JP2020517289A publication Critical patent/JP2020517289A/ja
Publication of JP2020517289A5 publication Critical patent/JP2020517289A5/ja
Priority to JP2024033480A priority Critical patent/JP2024075603A/ja
Application granted granted Critical
Publication of JP7457302B2 publication Critical patent/JP7457302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019558446A 2017-04-28 2018-04-25 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法 Active JP7457302B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024033480A JP2024075603A (ja) 2017-04-28 2024-03-06 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491487P 2017-04-28 2017-04-28
US62/491,487 2017-04-28
PCT/US2018/029302 WO2018200635A1 (en) 2017-04-28 2018-04-25 Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024033480A Division JP2024075603A (ja) 2017-04-28 2024-03-06 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法

Publications (3)

Publication Number Publication Date
JP2020517289A JP2020517289A (ja) 2020-06-18
JP2020517289A5 true JP2020517289A5 (https=) 2021-06-10
JP7457302B2 JP7457302B2 (ja) 2024-03-28

Family

ID=63918677

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019558446A Active JP7457302B2 (ja) 2017-04-28 2018-04-25 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法
JP2024033480A Pending JP2024075603A (ja) 2017-04-28 2024-03-06 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024033480A Pending JP2024075603A (ja) 2017-04-28 2024-03-06 Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法

Country Status (13)

Country Link
US (2) US11932867B2 (https=)
EP (2) EP3615674B1 (https=)
JP (2) JP7457302B2 (https=)
AU (2) AU2018258061B2 (https=)
CA (1) CA3061614A1 (https=)
DK (1) DK3615674T3 (https=)
ES (1) ES2981611T3 (https=)
FI (1) FI3615674T3 (https=)
HR (1) HRP20240806T1 (https=)
HU (1) HUE069314T2 (https=)
LT (1) LT3615674T (https=)
SI (1) SI3615674T1 (https=)
WO (1) WO2018200635A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3615674T (lt) 2017-04-28 2024-09-25 The Regents Of The University Of Colorado, A Body Corporate Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome
KR20240023035A (ko) 2021-05-10 2024-02-20 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 자가면역 치료를 위한 hla 조작 방법 및 조성물
WO2025195458A1 (en) * 2024-03-20 2025-09-25 Nanjing Legend Biotech Co., Ltd. Methods for producing immune-compatible cells

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US5965787A (en) * 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6667175B1 (en) 1999-06-15 2003-12-23 The Trustees Of Columbia University Generation of antigen specific T suppressor cells for treatment of rejection
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
US20060062761A1 (en) 2001-03-02 2006-03-23 Carr Francis J Modified interferon alpha with reduced immunogenicity
US8790345B2 (en) 2007-08-21 2014-07-29 Zimmer, Inc. Titanium alloy with oxidized zirconium for a prosthetic implant
US9175280B2 (en) 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US8969254B2 (en) * 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
JP6598860B2 (ja) * 2014-08-06 2019-10-30 カレッジ オブ メディシン ポチョン チャ ユニバーシティ インダストリー−アカデミック コーオペレイション ファウンデーション Hlaをコードする遺伝子のヌクレアーゼ媒介編集により作製される免疫適合性細胞
CN108026526B (zh) * 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
CA2996887A1 (en) 2015-09-11 2017-03-16 Agenus Inc. Engineered host cells and methods of use thereof
LT3615674T (lt) 2017-04-28 2024-09-25 The Regents Of The University Of Colorado, A Body Corporate Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome
RU2763798C1 (ru) 2017-12-23 2022-01-11 Рубиус Терапьютикс, Инк. Искусственные антигенпрезентирующие клетки и способы их применения
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
GB201807410D0 (en) 2018-05-04 2018-06-20 Univ Oxford Innovation Ltd Diagnostic method and therapy
US11918610B2 (en) 2018-06-29 2024-03-05 Viktor Veniaminovich Tets Methods for diagnosis and treatment of type 1 diabetes
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ, インコーポレイテッド T細胞調節多量体ポリペプチド及びその使用方法
WO2020181272A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
EP3935079A4 (en) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
KR20240023035A (ko) 2021-05-10 2024-02-20 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 자가면역 치료를 위한 hla 조작 방법 및 조성물

Similar Documents

Publication Publication Date Title
Ferrari et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking
RU2744603C2 (ru) Композиции, повышающие число копий вектора (чкв), и способы их применения
JP2022184901A (ja) モジュラーAAV送達システムによるCRISPR-Casゲノム編集
JP2020508685A (ja) サプレッサーtRNA及びデアミナーゼによる変異のRNAターゲティング
JP2019500043A5 (https=)
JP2021521855A5 (https=)
JP2022545950A5 (https=)
JP2021532776A5 (https=)
JP7633155B2 (ja) 人工トランス活性化因子による選択
CN114245803A (zh) 用于重构小神经胶质细胞的方法和组合物
CN108883136A (zh) Vcn增强子组合物及其使用方法
JP2020517289A5 (https=)
JP2021503015A5 (https=)
CN106350541B (zh) 先天性免疫缺陷基因治疗载体构建方法及其用途
CN113646006A (zh) 用于营养不良型大疱性表皮松解症的治疗剂
CN111718420B (zh) 一种用于基因治疗的融合蛋白及其应用
WO2025261231A1 (zh) 高度靶向人类HLA-A基因的sgRNA、其组合物及应用
CN117716026A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
US20230310555A1 (en) Compositions for genome editing and methods of use thereof
FI3615674T3 (fi) Menetelmiä reumatoidin artriitin hoitoon HLA-geenin RNA-ohjattua genomin muokkausta käyttämällä
JP2017518056A (ja) 感染性rnaウイルスを迅速に生成するための方法
Dodd et al. Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells
KR20250166122A (ko) 게놈 편집을 위한 조성물 및 방법
CN118374457A (zh) 永生化猪胎儿成纤维细胞系及其构建方法与应用
WO2023046086A1 (zh) 一种碱基编辑系统及其应用